- Home
- LBRDK vs BMRN Comparison
LBRDK vs BMRN Comparison
Compare LBRDK & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBRDK
- BMRN
- Stock Information
- Founded
- LBRDK 2014
- BMRN 1996
- Country
- LBRDK United States
- BMRN United States
- Employees
- LBRDK N/A
- BMRN N/A
- Industry
- LBRDK Cable & Other Pay Television Services
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- LBRDK Telecommunications
- BMRN Health Care
- Exchange
- LBRDK Nasdaq
- BMRN Nasdaq
- Market Cap
- LBRDK 12.1B
- BMRN 12.1B
- IPO Year
- LBRDK N/A
- BMRN 1999
- Fundamental
- Price
- LBRDK $95.30
- BMRN $58.00
- Analyst Decision
- LBRDK Buy
- BMRN Buy
- Analyst Count
- LBRDK 2
- BMRN 22
- Target Price
- LBRDK $80.00
- BMRN $93.43
- AVG Volume (30 Days)
- LBRDK 1.5M
- BMRN 2.1M
- Earning Date
- LBRDK 08-07-2025
- BMRN 08-04-2025
- Dividend Yield
- LBRDK N/A
- BMRN N/A
- EPS Growth
- LBRDK 6.21
- BMRN 152.82
- EPS
- LBRDK 6.26
- BMRN 2.71
- Revenue
- LBRDK $1,037,000,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- LBRDK $5.22
- BMRN $12.23
- Revenue Next Year
- LBRDK $2.34
- BMRN $9.99
- P/E Ratio
- LBRDK $15.54
- BMRN $21.48
- Revenue Growth
- LBRDK 5.82
- BMRN 19.36
- 52 Week Low
- LBRDK $52.78
- BMRN $52.93
- 52 Week High
- LBRDK $104.00
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- LBRDK 49.39
- BMRN 59.75
- Support Level
- LBRDK $96.67
- BMRN $56.76
- Resistance Level
- LBRDK $101.46
- BMRN $59.98
- Average True Range (ATR)
- LBRDK 2.45
- BMRN 1.44
- MACD
- LBRDK -0.07
- BMRN 0.62
- Stochastic Oscillator
- LBRDK 40.64
- BMRN 81.47
About LBRDK Liberty Broadband Corporation Class C
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.